Treatment Commences in Second Patient Cohort in Cynata’s World First Clinical Trial

Biotech Investing

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that the first patient in Cohort B has been treated with CYP-001, the Company’s first mesenchymal stem cell (MSC) product for steroid-resistant acute graft-versus-host disease (GvHD). As quoted in the press release: Dr Kilian Kelly, Cynata’s Vice President of Product Development, said “The …

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that the first patient in Cohort B has been treated with CYP-001, the Company’s first mesenchymal stem cell (MSC) product for steroid-resistant acute graft-versus-host disease (GvHD).
As quoted in the press release:

Dr Kilian Kelly, Cynata’s Vice President of Product Development, said “The treatment of the first patient in Cohort B, and the ninth patient overall in this trial, is another milestone and value catalyst for the Company, bringing us closer to determining how safe and effective CYP-001 is in this devastating disease. In light of the very encouraging results from the initial cohort, and the higher dose level in Cohort B, we look forward to the final data with optimism.”

Click here to read the full press release.

The Conversation (0)
×